New Strong Buy Stocks for July 3rd
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 03 2024
0mins
Source: NASDAQ.COM
- Stocks Added to Zacks Rank #1 List: Five stocks, including Mondi plc, Mueller Water Products, Sarepta Therapeutics, Amtech Systems, and Cool Company Ltd., have been added to the Zacks Rank #1 (Strong Buy) List.
- Earnings Estimates Increase: The Zacks Consensus Estimate for current year earnings has increased for these companies over the last 60 days: Mondi plc by 12.7%, Mueller Water Products by 14.5%, Sarepta Therapeutics by 61.3%, Amtech Systems by 70.6%, and Cool Company Ltd. by 10.7%.
- Zacks Investment Research Offer: Zacks Investment Research offers access to all their picks for $1 for 30 days with no obligation to spend more, aiming to introduce users to their portfolio services like Surprise Trader and Technology Innovators.
- Free Stock Analysis Reports: Free stock analysis reports are available for Amtech Systems, Sarepta Therapeutics, Mueller Water Products, Mondi plc, and Cool Company Ltd.
- Disclaimer: The views and opinions expressed in the article belong to the author and may not necessarily reflect those of Nasdaq, Inc.
Analyst Views on SRPT
Wall Street analysts forecast SRPT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRPT is 20.80 USD with a low forecast of 5.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
4 Buy
10 Hold
4 Sell
Hold
Current: 21.790
Low
5.00
Averages
20.80
High
45.00
Current: 21.790
Low
5.00
Averages
20.80
High
45.00
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
